Amgen acquired Netherlands-based Dezima Pharma for $300M upfront with up to $1.25B in milestones plus royalties, adding TA-8995 (obicetrapib), an oral CETP inhibitor showing 45-48% LDL-C reduction in Phase 2b. Amgen discontinued the program ~2017; rights later reacquired by NewAmsterdam Pharma.